JP2014528700A5 - - Google Patents

Download PDF

Info

Publication number
JP2014528700A5
JP2014528700A5 JP2014521695A JP2014521695A JP2014528700A5 JP 2014528700 A5 JP2014528700 A5 JP 2014528700A5 JP 2014521695 A JP2014521695 A JP 2014521695A JP 2014521695 A JP2014521695 A JP 2014521695A JP 2014528700 A5 JP2014528700 A5 JP 2014528700A5
Authority
JP
Japan
Prior art keywords
inhibitor
composition
composition according
seq
stranded rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014521695A
Other languages
English (en)
Japanese (ja)
Other versions
JP6313203B2 (ja
JP2014528700A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/046928 external-priority patent/WO2013012806A2/en
Publication of JP2014528700A publication Critical patent/JP2014528700A/ja
Publication of JP2014528700A5 publication Critical patent/JP2014528700A5/ja
Application granted granted Critical
Publication of JP6313203B2 publication Critical patent/JP6313203B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014521695A 2011-07-18 2012-07-16 Ａｌｕ−ｒｎａ誘導変性からの細胞の保護及び細胞保護用阻害剤 Active JP6313203B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161508867P 2011-07-18 2011-07-18
US61/508,867 2011-07-18
US201161543038P 2011-10-04 2011-10-04
US61/543,038 2011-10-04
PCT/US2012/046928 WO2013012806A2 (en) 2011-07-18 2012-07-16 Protection of cells from alu-rna-induced degenereation and inhibitors for protecting cells

Publications (3)

Publication Number Publication Date
JP2014528700A JP2014528700A (ja) 2014-10-30
JP2014528700A5 true JP2014528700A5 (enExample) 2015-08-20
JP6313203B2 JP6313203B2 (ja) 2018-04-18

Family

ID=47558691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014521695A Active JP6313203B2 (ja) 2011-07-18 2012-07-16 Ａｌｕ−ｒｎａ誘導変性からの細胞の保護及び細胞保護用阻害剤

Country Status (9)

Country Link
US (1) US9453226B2 (enExample)
EP (2) EP3366302B1 (enExample)
JP (1) JP6313203B2 (enExample)
CN (1) CN103889461B (enExample)
AU (1) AU2012284223B2 (enExample)
CA (2) CA2842034C (enExample)
ES (1) ES2907620T3 (enExample)
PT (1) PT3366302T (enExample)
WO (1) WO2013012806A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11512326B2 (en) 2009-05-26 2022-11-29 University Of Florida Research Foundation, Incorporated Small angiotensin peptide expression system in mammalian cells
CN103328633B (zh) 2010-10-22 2018-07-10 成均馆大学校产学协力团 诱导rna干扰的核酸分子及其用途
US9707235B1 (en) 2012-01-13 2017-07-18 University Of Kentucky Research Foundation Protection of cells from degeneration and treatment of geographic atrophy
EP2847215A1 (en) * 2012-05-07 2015-03-18 Synthes GmbH Methods and devices for treating intervertebral disc disease
CN108148838B (zh) 2012-05-22 2026-07-31 奥利克斯医药有限公司 具有细胞内穿透能力的诱导rna干扰的核酸分子及用途
US9441223B2 (en) 2012-09-05 2016-09-13 Cold Spring Harbor Laboratory, LLC Transposable elements, TDP-43, and neurodegenerative disorders
US10981961B2 (en) 2013-03-11 2021-04-20 University Of Florida Research Foundation, Incorporated Delivery of card protein as therapy for occular inflammation
US9326983B2 (en) 2013-08-01 2016-05-03 University Of Kentucky Research Foundation Compositions and methods for treating retinal degradation
WO2015095609A1 (en) * 2013-12-19 2015-06-25 The J. David Gladstone Institute Inhibition of interferon-gamma-inducible protein 16 (ifi16)
US11053291B2 (en) 2014-02-19 2021-07-06 University Of Florida Research Foundation, Incorporated Delivery of Nrf2 as therapy for protection against reactive oxygen species
EP4050020A1 (en) * 2014-03-11 2022-08-31 University of Florida Research Foundation, Inc. Aav-expressed m013 protein as an anti-inflammatroy therapeutic for use in a method of treating inflammatory ocular disease
EP3177732A4 (en) * 2014-08-08 2018-04-25 ModernaTX, Inc. Compositions and methods for the treatment of ophthalmic diseases and conditions
US11219623B2 (en) 2015-02-26 2022-01-11 University Of Kentucky Research Foundation Inflammasome inhibition for the treatment of Parkinson's disease, Alzheimer's disease and multiple sclerosis
ES2879678T3 (es) 2015-02-26 2021-11-22 Univ Kentucky Res Found Composiciones y procedimientos para el tratamiento de la degradación retiniana
JP7085712B2 (ja) * 2015-09-03 2022-06-17 ビー．ジー． ネゲヴ テクノロジーズ アンド アプリケーションズ リミテッド、アット ベン－グリオン ユニヴァーシティ Ｖｄａｃ１由来ペプチドの類似体
WO2017081686A1 (en) 2015-11-10 2017-05-18 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Means and methods for reducing tumorigenicity of cancer stem cells
JP7027311B2 (ja) * 2015-11-16 2022-03-01 オリックス ファーマシューティカルズ，インコーポレーテッド ＭｙＤ８８又はＴＬＲ３を標的とするＲＮＡ複合体を使用した加齢黄斑変性の治療
WO2017134525A1 (en) 2016-02-02 2017-08-10 Olix Pharmaceuticals, Inc. TREATMENT OF ATOPIC DERMATITIS AND ASTHMA USING RNA COMPLEXES THAT TARGET lL4Rα, TRPA1, OR F2RL1
CN109415413A (zh) * 2016-06-07 2019-03-01 耶路撒冷希伯来大学伊森姆研究发展有限公司 髓样分化因子88(myd88)的主链环化抑制肽
US11130951B2 (en) * 2016-06-09 2021-09-28 The General Hospital Corporation Modulating the cellular stress response
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
US20190185820A1 (en) * 2016-08-26 2019-06-20 The Regents Of The University Of California Compositions and Methods for Inhibiting Stem Cell Aging
FI3558335T3 (fi) 2016-12-23 2023-07-19 Casp Aid Inc Kaspaasi-1-inhibitio ja sen käyttötarkoituksia neurologisten tilojen ehkäisyyn ja hoitoon
WO2018146557A2 (en) 2017-02-10 2018-08-16 Dong Ki Lee Long double-stranded rna for rna interference
GB2561540A (en) 2017-03-13 2018-10-24 Nodthera Ltd Chemical compounds
US11613756B2 (en) * 2017-04-03 2023-03-28 Duke University Compositions and methods for differential induction of cell death and interferon expression
EP3672579A4 (en) * 2017-10-10 2021-06-23 University of Virginia Patent Foundation COMPOSITIONS AND METHODS OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHICAL ATROPHY
EP3813805A4 (en) * 2018-06-27 2021-08-25 Children's Medical Center Corporation INFLAMMATION INHIBITION COMPOUNDS
KR102138256B1 (ko) * 2018-09-13 2020-08-13 한국과학기술연구원 케스페이즈-1 활성 측정용 프로브, 이를 포함하는 염증성 질환 진단용 조성물
US20210348164A1 (en) * 2018-10-09 2021-11-11 University Of Virginia Patent Foundation Endogenous cytoplasmic alu complementary dna in age-related macular degeneration
WO2020089906A1 (en) 2018-11-01 2020-05-07 National Institute For Biotechnology In The Negev Ltd. Vdac1 silencing molecules and use thereof
CN110305957B (zh) * 2019-08-22 2022-07-29 中国水产科学研究院淡水渔业研究中心 一种鉴定黄颡鱼脂肪肝程度的试剂盒及其鉴定方法
AU2020340298A1 (en) * 2019-08-23 2022-03-24 University Of Virginia Patent Foundation DDX17 and NLRC4 targeting for inflammatory diseases
EP4088742A4 (en) * 2020-01-06 2024-07-10 Seasun Therapeutics COMPOSITION FOR PREVENTING OR TREATING MACULAR DEGENERATION CONTAINING A CELL-PERMEABLE NUCLEIC ACID COMPLEX AS ACTIVE SUBSTANCE
US20230355553A1 (en) * 2020-02-11 2023-11-09 University Of Virginia Patent Foundation Compositions and methods for treating and/or preventing ocular disorders
CN111358950A (zh) * 2020-03-20 2020-07-03 厦门大学 Caspase-1及ASC/Caspase-8作为靶点的应用
EP4192952A1 (en) * 2020-08-10 2023-06-14 Novartis AG Treatments for retinal degenerative diseases
CA3201637A1 (en) 2020-11-18 2022-05-27 Novartis Ag Bispecific antibodies for use in treatment of nlrc4-gof inflammasomapathy
CN114099683B (zh) * 2021-12-28 2022-12-16 首都医科大学附属北京同仁医院 Nox2特异性抑制剂在制备视网膜变性药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
WO2000047218A1 (en) * 1999-02-11 2000-08-17 The Trustees Of The University Of Pennsylvania Regulation of photoreceptor degeneration
GB9930616D0 (en) * 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US20030186903A1 (en) * 2001-11-23 2003-10-02 Isis Pharmaceuticals Inc. Antisense modulation of MyD88 expression
CA2472927A1 (en) * 2002-01-10 2003-07-17 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw A novel splice variant of myd88 and uses thereof
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
WO2005105133A2 (en) * 2004-04-23 2005-11-10 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
CA2590750A1 (en) * 2004-12-20 2006-06-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Myd88 homodimerization inhibitors
US7879992B2 (en) * 2005-01-31 2011-02-01 Isis Pharmaceuticals, Inc. Modification of MyD88 splicing using modified oligonucleotides
EP1746167A1 (en) * 2005-07-20 2007-01-24 Apoxis SA Method for the identification of compounds susceptible to inhibit inflammation
WO2007077042A1 (en) * 2006-01-06 2007-07-12 Topotarget Switzerland Sa New method for the treatment of gout or pseudogout
CA2671524A1 (en) 2006-12-01 2008-06-12 Loma Linda University Medical Center Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration
WO2008150431A1 (en) * 2007-05-29 2008-12-11 Yale University Il- 18 and protein kinase r inhibition for the treatment of copd
US20090227487A1 (en) * 2008-03-05 2009-09-10 Jeremy Pearl Methods for the control of macrophage-associated inflammation
US20100092486A1 (en) * 2008-08-08 2010-04-15 Idera Pharmaceuticals, Inc. Modulation of myeloid differentation primary response gene 88 (myd88) expression by antisense oligonucleotides
US20130137642A1 (en) * 2010-04-23 2013-05-30 Demetrios Vavvas Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
US8809517B2 (en) 2010-06-01 2014-08-19 University Of Kentucky Research Foundation Method of inhibiting Alu RNA and therapeutic uses thereof
US20120177632A1 (en) * 2011-01-10 2012-07-12 Shinohara Mari L Methods of optimizing disease treatment

Similar Documents

Publication Publication Date Title
JP2013536015A5 (enExample)
JP2012525415A5 (enExample)
JP2013520405A5 (enExample)
JP2009501797A5 (enExample)
JP2006515351A5 (enExample)
HRP20170531T1 (hr) Novi terapijski pristupi za liječenje alzheimerove bolesti i povezanih poremećaja putem modulacije angiogeneze
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
JP2016508134A5 (enExample)
JP2022550670A5 (enExample)
HRP20120264T1 (hr) Farmaceutski sastavi neuroaktivnog steroida i njihove uporabe
JP2016539125A5 (enExample)
JP2015526467A5 (enExample)
US9415046B2 (en) Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods
WO2015138628A8 (en) Use of aav-expressed m013 protein as an anti-inflammatory therapeutic
JP2013515739A5 (enExample)
WO2007078443A3 (en) Methods of treating unwanted immune response with random copolymers
JP2018530574A5 (enExample)
ES3032941T3 (en) Treatment of hyperinflammatory syndrome
JP2019511496A5 (enExample)
WO2021174024A1 (en) Methods of treating iatrogenic autoimmune colitis
RU2018110647A (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
Emmi et al. Long-term efficacy and safety of anakinra in a patient with Behçet's disease and concomitant tuberculosis infection
RU2014132553A (ru) Фармацевтическая композиция для уменьшения осложнений применения стероидных препаратов при лечении офтальмологических заболеваний
JP2020533302A5 (enExample)
JP2019507775A5 (enExample)